Quest Diagnostics Incorporated
DGX
Peringkat dalam Saham
#930
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Harga Saham
$236.69
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$26.12B
Perubahan (1 hari)
0.80%
Perubahan (1 tahun)
28.19%
Negara
US
Perdagangan Quest Diagnostics Incorporated (DGX)
Kategori
Healthcare
Laba untuk Quest Diagnostics Incorporated (DGX)
Laba pada Jun 2026 TTM: $1.42B
Menurut laporan keuangan terbaru dari Quest Diagnostics Incorporated, laba saat ini perusahaan adalah $1.42B. Pada tahun 2024, perusahaan memperoleh laba sebesar $1.19B, peningkatan dibandingkan laba tahun 2023 sebesar $1.16B. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Quest Diagnostics Incorporated dari 2000 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $1.42B | 4.34% |
| 2025 | $1.36B | 13.90% |
| 2024 | $1.19B | 3.29% |
| 2023 | $1.16B | -9.62% |
| 2022 | $1.28B | -52.22% |
| 2021 | $2.68B | 36.65% |
| 2020 | $1.96B | 72.90% |
| 2019 | $1.13B | 22.35% |
| 2018 | $926.00M | -10.10% |
| 2017 | $1.03B | -5.16% |
| 2016 | $1.09B | -1.54% |
| 2015 | $1.10B | 29.92% |
| 2014 | $849.00M | -37.02% |
| 2013 | $1.35B | 26.17% |
| 2012 | $1.07B | 24.77% |
| 2011 | $856.30M | -27.70% |
| 2010 | $1.18B | -3.55% |
| 2009 | $1.23B | 20.50% |
| 2008 | $1.02B | 11.68% |
| 2007 | $912.40M | -11.70% |
| 2006 | $1.03B | 13.49% |
| 2005 | $910.45M | 9.02% |
| 2004 | $835.13M | 13.19% |
| 2003 | $737.80M | 36.03% |
| 2002 | $542.38M | 63.07% |
| 2001 | $332.60M | 65.49% |
| 2000 | $200.98M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $7.61B | 436.22% |
US
|
|
| $4.76B | 235.59% |
US
|
|
| $-252.70M | -117.81% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 16.84% |
US
|
